Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways
Author:
- 29 October 2009
- journal article
- review article
- Published by Springer Nature in Leukemia
- Vol. 24 (1) , 13-21
Abstract
T-cell malignancies, mainly known as T-cell acute lymphoblastic leukemia (T-ALL) and T-cell non-Hodgkin’s lymphoma (T-NHL), are aggressive tumors. Although the clinical outcome of the patients has improved dramatically with combination chemotherapy, significant challenges remain, including understanding of the factors that contribute to the malignant behavior of these tumor cells and developing subsequently optimal targeted therapy. Aberrant cell signal transduction is generally involved in tumor progression and drug resistance. This review describes the pathogenetic role of multiple cellular signaling pathways in T-cell malignancies and the potential therapeutic strategies based on the modulation of these key signaling networks.Keywords
This publication has 114 references indexed in Scilit:
- Cellular signaling perturbation by natural productsCellular Signalling, 2009
- CSL–MAML-dependent Notch1 signaling controls T lineage–specific IL-7Rα gene expression in early human thymopoiesis and leukemiaJournal of Experimental Medicine, 2009
- Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative diseaseImmunologic Research, 2008
- Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphomaAnnals of Oncology, 2008
- New insights into the roles of Stat5a/b and Stat3 in T cell development and differentiationSeminars in Cell & Developmental Biology, 2008
- Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemiaJournal of Experimental Medicine, 2008
- Critical roles of the PI3K/Akt signaling pathway in T cell developmentImmunology Letters, 2008
- Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemiaNature Medicine, 2007
- A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in gliomaCancer Cell, 2006
- NF-κB in cancer: from innocent bystander to major culpritNature Reviews Cancer, 2002